New prognostic factors in multiple myeloma

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

DHRS2 regulates epithelial-mesenchymal transition in breast cancer cells.

Molecular biology reports·2026

Esculin attenuates cholestatic liver injury and fibrosis in bile duct-ligated rats by modulating oxidative stress, inflammatory responses, and fibrogenic mediators.

Molecular biology reports·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026

Related Experiment Videos

New prognostic factors in multiple myeloma

Related Concept Videos

Effects of saline nebulization on SARS-CoV-2 RNA spreading and exhaled bio-aerosol particles in COVID-19 patients.

Anti-fibronectin aptamers improve the colonization of chitosan films modified with D-(+) Raffinose by murine osteoblastic cells.

Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.

Quantitative determination of micronization-induced changes in the solid state of lactose.

Chitosan scaffold modified with D-(+) raffinose and enriched with thiol-modified gelatin for improved osteoblast adhesion.

Ex vivo permeation of tamoxifen and its 4-OH metabolite through rat intestine from lecithin/chitosan nanoparticles.

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Heat shock protein family D member 1 (HSPD1) modulates ribosome-related pathways and protein synthesis in lung adenocarcinoma.

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Sex-specific associations of the bilirubin-to-albumin ratio with lung cancer risk: evidence from Cox regression and causal survival forest analysis.

DHRS2 regulates epithelial-mesenchymal transition in breast cancer cells.

Esculin attenuates cholestatic liver injury and fibrosis in bile duct-ligated rats by modulating oxidative stress, inflammatory responses, and fibrogenic mediators.

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Related Experiment Videos

New prognostic factors in multiple myeloma

Related Concept Videos

Related Articles